Online inquiry

IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8270MR)

This product GTTS-WQ8270MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GHR gene. The antibody can be applied in Growth hormone (GH) deficiency research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000163.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2690
UniProt ID P10912
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8270MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7145MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ13586MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ14242MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ15630MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ2036MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ12593MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ10405MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ7735MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW